Latest Development Programs News

Impact Minerals’ 50%-owned Alluminous project reveals a strong financial case for a staged US high purity alumina plant, projecting a post-tax NPV₈ of A$518 million and a 42.3% IRR under a modular development approach.

Phoslock Environmental Technologies has advanced a new range of lanthanum-enhanced phosphorus-binding products showing up to four times the capacity of current offerings, with pilot and manufacturing tests confirming strong performance and low lanthanum release. Field trials are underway, aiming for commercial sales in 2027.

Stonehorse Energy has sold its US Lone Star oil and gas interests for US$1.114 million, shifting focus to expanding its Drumheller development program in Alberta.

Brookside Energy has expanded its US production base by acquiring Lone Star’s oil and gas interests, adding 123 BOEPD of low-decline, cash-flowing assets without issuing new equity.

Nexalis Therapeutics reports a 52% rise in half-year losses to $1.3 million amid funding facility cancellation and clinical trial suspensions, highlighting ongoing cash flow challenges.

West Coast Silver has raised $6 million through an oversubscribed placement, enhancing its capacity to advance exploration and development at the high-grade Elizabeth Hill silver project.

Racura Oncology has launched patient enrolment at its first Korean site for the CPACS Phase 1 trial, aiming to accelerate recruitment and validate RC220’s safety and efficacy in a key oncology market.

BLS Pharmaceuticals (ASX: BLS) reported a standout FY26 with revenue surging 161% to $74.2 million and net profit more than tripling to $15.4 million, driven by expanded manufacturing and major international contracts including a $50 million German supply deal.

West Wits Mining has transitioned from developer to producer with first gold poured at Qala Shallows, backed by a $97 million project finance package and a resource base expanded to 7.24 million ounces.

Orbital Corporation has broadened its customer base and product lineup, positioning itself to capture growth in defence and commercial UAV markets with $3.2 million in expected sales for Q1 FY2027.

BluGlass Limited reported a 5% reduction in its net loss to A$10.39 million for FY26 despite a 10% revenue dip, boosted by new US defence and industry contracts and a significant capital raise to fund growth.

Alterity Therapeutics posted a 285% jump in revenue to A$1.72 million but also a 93% rise in net loss to A$23.4 million for FY2026. The company secured FDA alignment on a single pivotal Phase 3 trial for ATH434 in Multiple System Atrophy, setting the stage for trial start by year-end.